In 2020, when China’s EV population was only around 3 million, CDH keenly noticed that EV replacing petrol vehicle was destined, and seized the investment opportunity of TELD at an excellent time. “All the other investors were hesitated, but the VGC team made a thorough research, understood us the most”, and quickly drew a conclusion. So when everybody held negative attitude, CDH was the first to make the investment decision. After CDH’s investment, major policies such as “new infrastructure” and “carbon neutral” were launched, increasing the sales of EV rapidly. As the leading operator of charging network, TELD ranks 1st by total number of charging piles, total amount of electricity charged, and utilization rate. TELD’s unique technologies including “grouping control”, “bidirectional inverters”, “Microgrid” etc，can effectively balance the mismatches between supply and demand. TELD’s new concept of turning EVs into a “virtual power plant” will greatly promote China’s energy transformation.

GemPharmatech boasts the world's largest repository of mouse strain resources, ranking first in China's model animal sector with exceptionally high entry and competitive barriers, and a solid industry position. Its founder, Professor Gao Xiang, previously established the National Genetic Engineering Mouse Resource Bank and received the Second Prize of National Science and Technology Progress. In July 2019, CDH VGC made its initial Series A investment in GemPharmatech, accompanying the company as it grew into the world's largest mouse strain resource bank, gradually breaking the market dominance previously held by foreign companies. In April 2022, GemPharmatech successfully listed on the STAR Market. CDH VGC continues to leverage its extensive experience in the biopharmaceutical field to identify inflection points in sub-sectors, helping companies get on the right fast track and create value that genuinely benefits patients and society.

In 2011, with its expertise and sincerity, CDH stood out from dozens of investors and became the only financial investor of Kanghong Pharmaceutical. After the investment, the company's proprietary Class 1 innovative drug "Conbercept" was launched in China. This is China’s first domestic biological drug, with proprietary intellectual property rights, to be officially endorsed by WHO. This also broke the monopoly of imported drugs and greatly reduced patient expenditures and increased utilization rates, creating huge social impact as well as economic value. At the same time, Conbercept brought rapid growth in revenue, which helped Kanghong completed the A-share listing in 2015. CDH has accurately catch the turning point of the pharmaceutical industry in China, where innovative drugs took the place of generics as the new market dominator. It is also a remarkable milestone for Kanghong to realize its value from R&D to market as a leader in China’s pharmaceutical industry. CDH's "deep dive" industry research, "sharp and insightful“ understanding of industrial trends, "precisely positioning" of industry leaders, and stronge execution of "fundraising, investment, management and exit" eventually made a huge success out of the investment in Kanghong.